中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

23 records (took 0.019 seconds)

    Method for preparing pluripotent stem cell-derived cardiomyocyte population
    15.
    发明授权
    Method for preparing pluripotent stem cell-derived cardiomyocyte population 有权

    公开(公告)号：US10696948B2

    公开(公告)日：2020-06-30

    申请号：US15511275

    申请日：2015-09-14

    Applicant: OSAKA UNIVERSITY

    Inventor： Yukiko Ochi ,  Kiyotoshi Sekiguchi ,  Shigeru Miyagawa ,  Yoshiki Sawa ,  Antti Markus Siltanen

    IPC: C12N5/077 ,  A61K35/34 ,  C12N5/074

    Abstract: The present invention provides a method for preparing a clinically applicable, safe and less damaged cardiomyocyte population through a brief and simple procedure from a cell population obtained by induced differentiation of pluripotent stem cells into cardiomyocytes. The present invention relates to a method for preparing a cardiomyocyte population, the method comprising the steps of: (1) inducing pluripotent stem cells to differentiate into cardiomyocytes, (2) bringing a cell population obtained by the induced differentiation into contact with a laminin selected from the group consisting of laminin α2β1γ1, laminin α2β2γ1, laminin α1β1γ1 and laminin α1β2γ1, or a fragment thereof having integrin binding activity, and (3) retrieving cells adherent to the laminin or the laminin fragment.

    METHOD FOR EVALUATING CARDIOMYOCYTES USING RAMAN SCATTERING
    18.
    发明申请
    METHOD FOR EVALUATING CARDIOMYOCYTES USING RAMAN SCATTERING 有权

    公开(公告)号：US20250093326A1

    公开(公告)日：2025-03-20

    申请号：US18727951

    申请日：2023-01-12

    Applicant: OSAKA UNIVERSITY ,  National Institute of Advanced Industrial Science and Technology

    Inventor： Katsumasa Fujita ,  Kazuki Bando ,  Li Liu ,  Junjun Li ,  Yoshiki Sawa ,  Shigeru Miyagawa ,  Yasunori Nawa ,  Satoshi Fujita

    IPC: G01N33/483 ,  C12N5/077 ,  G01N21/65

    Abstract: Method for evaluating cardiomyocytes using Raman scattering: a Raman spectrum of cardiomyocytes artificially induced to differentiate from pluripotent stem cells is acquired, an intensity of Raman-scattered light for a protein containing at least one of heme b and heme c as a prosthetic group is acquired from the Raman spectrum, and a state of progress of maturation of the cardiomyocytes is evaluated on the basis of the intensity of the Raman-scattered light. Method for evaluating differentiation into cardiomyocytes using Raman scattering: cells which are pluripotent stem cells are artificially induced to differentiate into cardiomyocytes, a Raman spectrum of the cells induced to differentiate is acquired, an intensity of Raman-scattered light for at least one of heme b and heme c is acquired from the Raman spectrum, and a state of progress of differentiation of the cells into cardiomyocytes is evaluated on the basis of the intensity of the Raman-scattered light.

    Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
    20.
    发明授权
    Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure 有权

    公开(公告)号：US11826401B2

    公开(公告)日：2023-11-28

    申请号：US16477878

    申请日：2018-01-26

    Applicant: StemRIM Inc. ,  OSAKA UNIVERSITY

    Inventor： Katsuto Tamai ,  Yoshiki Sawa ,  Shigeru Miyagawa ,  Takashi Kido ,  Takasumi Goto ,  Takehiko Yamazaki

    IPC: A61K38/00 ,  C07K14/00 ,  A61K38/19 ,  A61P9/10

    CPC classification number: A61K38/19 ,  A61P9/10

    Abstract: The present inventors have found that HMGB1 fragment peptides having a particular amino acid sequence exhibit the effects of improvement of cardiac function, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of dilated cardiomyopathy, that the particular HMGB1 fragment peptides also exhibit the effects of improvement of cardiac function, inhibition of cardiomegaly, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of ischemic cardiomyopathy caused by old myocardial infarction, and that the particular HMGB1 fragment peptides exhibit the effects of inhibition of cardiomyocyte hypertrophy and inhibition of myocardial fibrosis in an animal model of hypertensive cardiomyopathy. Based on these findings, pharmaceutical compositions are provided for the prevention and/or treatment of cardiomyopathy and old myocardial infarction and chronic heart failure resulting therefrom, which comprise an HMGB1 fragment peptide having a particular amino acid sequence.

Patent Agency Ranking